At the time of establishing the Clinic, its Board of Directors recognised that for radiowave therapy to have its place with conventional treatments, it would need to undergo a continuum of rigorous research (refer Directors message).
This meant that 2 projects would need to be funded:
- the Clinic as an option for cancer patients;
- and a research organisation to ensure that a number of aspects and facts about radiowave therapy were better understood and articulated.
So what exactly are the functions of the Radiowave Therapy Research Institute (RTRI)? To answer this question some background is needed.
Dr Holt the founder of radiowave therapy claimed to have treated thousands of patients, many with successful treatment outcomes. However, in the 30 years Dr Holt treated patients neither he, nor anyone else, entered into a programme of detailed research at the laboratory level and progressed this research through clinical trials and then published the results.
Dr Holt did undertake a myriad of tests in his own right, and has written extensively on his treatments and their benefits, but this level of evidencing does not meet the rigor of the processes that govern how medical research is conducted.
So in a sense it is like an eligibility test for the medical community, which in the case of radiowave therapy has not occurred.
To be clear, this has little to do with the fact that patients have benefited from radiowave treatments.
It simply means that there is, in a sense, a research void which needs to be filled. To achieve this, the RTRI has a mandate to sponsor studies and research projects in all aspects of radiowave therapy and to ensure the results are independently published in peer reviewed journals. Obviously a positive research result is expected as pilot studies and the existing treatment have both yielded results already. Nevertheless the formality of due process is still valid.
So reading on, it is important you keep in mind that there are two forms of radiowave therapy developed by Dr Holt – with the common factor being the application of 434 MHz radiowaves – and both treatments will be researched.
The following information describes in more detail the aims and projects of the RTRI:
The RTRI’s radiowave therapy research involves a number of projects with four broad objectives: Measure clinical and quality-of-life (QoL) factors compare the side effects of radiowave therapy with conventional treatments, such as chemotherapy and full-dose radiotherapy document the benefits and outcomes of the therapy publish the results.
The initial three year business plan adopted by the Institute is based on a Research Programme which included sponsoring Universities and other Industry Professionals to conduct:
- in-vitro research
- A comprehensive review of the efficacy of conventional cancer treatments (for comparative analyses with Radiowave Therapy)
- A Clinical Outcomes Analysis of Radiowave Therapy Quality Of Life Studies of radiowave therapy
Further stages of research will be sponsored by the RTRI with the next stage to be completed in 2014. The eventual aim is to conduct clinical trials and as a result of published findings, be able identify where in relation to cancer treatment radiowave therapy has its place. The obvious end point is to gain broader acceptance of the modalities with the mainstream medical community.
The programme of research outlined may also be extended at some future date to study other non-cancer diseases for which radiowave therapy is claimed to have an effect. This broadening of the research scope would require modifications and extensions to the protocols, data management systems, sponsorships and contracts which currently exist in relation to the Institute’s cancer research.
The Clinic cannot comment at this stage on the quality, context, terms of reference or relevance of any previous literature reviews such as those conducted by the National Health and Medical Research Council (NHMRC) in relation to radiowave therapy. However, the treatment modalities are considered safe and this is amply demonstrated by the Medicare support for the treatments during years of Dr Holt’s practice, until the time of his retirement.
There are many past patients of radiowave therapy who act to testify to the importance of the research the RTRI is undertaking.
For more information about radiowave therapy research visit www.the-institute.com.au